Rose Parisi

Ms. Rose Parisi

ALBANY MEDICAL COLLEGE
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2024 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
HSHemali Shah
Hemali Shah
Rose ParisiRose Parisi
Rose Parisi
EMEric Mukherjee
Eric Mukherjee
EPElizabeth J. Phillips
Elizabeth J. Phillips
RDRoni P. Dodiuk-Gad
Roni P. Dodiuk-Gad
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the most severe cutaneous adverse reactions that are typically drug-induced in adults. Both SJS and TEN have high morbidity and mortality rates. SJS/TEN imposes clinical challenges for physicians managing patients suffering from this condition, both because it is rare and because it is a rapidly progressing systemic disease with severe cutaneous, mucosal, and systemic manifestations. Although many cases of SJS/TEN have been reported in the literature, there is no consensus regarding diagnostic criteria or treatment. Significant progress has been made in understanding its genetic predisposition and pathogenesis. This review is intended to provide physicians with a comprehensive but practical SJS/TEN roadmap to guide diagnosis and management. We review data on pathogenesis, reported precipitating factors, presentation, diagnosis, and management SJS/TEN focusing on what is new over the last 5 years.

8 May 2023 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
Rose ParisiRose Parisi
Rose Parisi
HSHemali Shah
Hemali Shah
Alexander NavariniAlexander Navarini
Alexander Navarini
BMBeda Muehleisen
Beda Muehleisen
MZMichael Ziv
Michael Ziv
RDRoni P. Dodiuk-Gad
Roni P. Dodiuk-Gad

18 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RPRoshal Patel
Roshal Patel
Rose ParisiRose Parisi
Rose Parisi
VVVivek Verma
Vivek Verma
RKRamez Kouzy
Ramez Kouzy
JJJoseph Abi Jaoude
Joseph Abi Jaoude
ELEthan Ludmir
Ethan Ludmir
Prior malignancy exclusion criteria (PMEC) are often utilized in cancer clinical trials; however, the incidence of PMEC and the association of PMEC with trial participant age disparities remain poorly understood. This study aimed to identify age disparities in oncologic randomized clinical trials as a result of PMEC. Using a comprehensive collection of modern phase III cancer clinical trials obtained via ClinicalTrials.gov, we assessed the incidence and covariates associated with trials excluding patients with prior cancers within 5+ years from registration (PMEC-5). Using the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database, we further sought to determine the correlation between PMEC-5 and age disparities. PMEC-5 were used in 41% of all trials, with higher PMEC-5 utilization among industry-supported trials as well as trials evaluating a targeted therapy. Comparing trial patient median ages with population-matched median ages by disease site and time-period, we assessed the association between PMEC-5 and age disparities among trial participants. PMEC-5 were independently associated with heightened age disparities, which further worsened with longer exclusionary timeframes. Together, PMEC likely contribute to age disparities, suggesting that eligibility criteria modernization through narrower PMEC timeframes may work toward reducing such disparities in cancer clinical trial enrollment.

24 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Rose ParisiRose Parisi
Rose Parisi
HSHemali Shah
Hemali Shah
NSNeil H. Shear
Neil H. Shear
MZMichael Ziv
Michael Ziv
AMAlina Markova
Alina Markova
RDRoni P. Dodiuk-Gad
Roni P. Dodiuk-Gad
The rapid evolution of anti-cancer therapy (including chemotherapy, targeted therapy, and immunotherapy) in recent years has led to a more favorable efficacy and safety profile for a growing cancer population, and the improvement of overall survival and reduction of morbidity for many cancers. Anti-cancer therapy improves outcomes for cancer patients; however, many classes of anti-cancer therapy have been implicated in the induction of bullous dermatologic adverse events (DAE), leading to reduced patient quality of life and in some cases discontinuation of life-prolonging or palliative therapy. Timely and effective management of adverse events is critical for reducing treatment interruptions and preserving an anti-tumor effect. Bullous DAE may be limited to the skin or have systemic involvement with greater risk of morbidity and mortality. We present the epidemiology, diagnosis, pathogenesis, and management of bullous DAE secondary to anti-cancer therapies to enable clinicians to optimize management for these patients.

21 October 2022 in Leukemia Research
Verified
Journal Article
Closed access
Rose ParisiRose Parisi
Rose Parisi
ECEmily A. Cowen
Emily A. Cowen
JSJoseph R. Stoll
Joseph R. Stoll
HZHaoling Zhu
Haoling Zhu
SDStephen Dusza
Stephen Dusza
AMAlina Markova
Alina Markova

26 December 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
Rose ParisiRose Parisi
Rose Parisi
RPRoshal Patel
Roshal Patel
GRGavrielle Rood
Gavrielle Rood
ABAcacia Bowden
Acacia Bowden
GTGeorge Turco
George Turco
LWLauren Weintraub
Lauren Weintraub